Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Breast Cancer, Multiple Myeloma, Prostate Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring bone lesions, breast cancer, multiple myeloma, prostate cancer, bone metastases, pain
Eligibility Criteria
Inclusion Criteria Signed informed consent Greater than 18 years of age Proof of breast cancer, multiple myeloma or prostate cancer Diagnosis of at least one cancer-related bone lesion If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception ECOG performance status of 0,1 or 2 Ability to read, understand and write English or Spanish language Normal renal function Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria clinically symptomatic brain metastases hypersensitivity to Zometa or other bisphosphonates pregnant or lactating
Sites / Locations
- Stockton Hematology Oncology Medical Group
- Osceola Cancer Center
- Nevada Cancer Center
- Hematology-Oncology Associates PC
- New Mexico Oncology Hematology Consultants
- Hematology Oncology Associates, PC
- Virginia Physicians, Inc